The first clinical trial of EHP-101, an investigational cannabinoid derived treatment for multiple sclerosis (MS), has been successfully completed. EHP-101 is a synthetic derivative compound of cannabidiol (CBD), one of the non-psychoactive components of the cannabis plant that has attracted increased scientific interest in recent years. Its different biological activities are believed to be beneficial in MS.
Emerald Health Pharmaceuticals (EHP) announced that in the trial EHP-101 was safe and well-tolerated in healthy volunteers, supporting further clinical development in future Phase 2 trials. Emerald Health Pharmaceuticals specialises in developing cannabinoid-derived pharmaceutical drugs like EHP-101. The company is currently preparing the launch of Phase 2 studies to explore the safety and impact of EHP-101 in patients with MS. The first Phase 2 trial is expected to begin by the end of 2019.
Studies in mice models of MS have demonstrated that treatment with EHP-101 could effectively reduce the amount of several genes involved in MS, including inflammatory molecules and proteins implicated in cellular adhesion to other cells or the extracellular matrix, which provides structural and biochemical support to cells.
Data also revealed that the EHP-101 could prevent microgliosis, a nonspecific and intense reaction by microglia which are immune cells of the central nervous system — in response to damage.
The recently completed Phase 1 clinical trial the investigational compound was well-tolerated, “with only mild to moderate side effects observed with increasing dose levels.” Detailed Phase 1 results are expected to be announced before the end of 2019, with accompanying presentations at scientific conferences.
Source: MS-UK 30/08/19